Key result
IQCA-TASS formed nanoparticles in rat plasma and induced no toxic reaction at 1000 times the minimal effective dose, indicating potential as a safe nano-medicine for targeting thrombus.
Answers are grounded in this paper and cite their sources.
IQCA-TASS demonstrates preclinical safety and potential as a targeted nano-medicine for delivering anti-thrombotic and anti-inflammatory agents to thrombi.
, a dose of 1000 times the minimal effective dose, IQCA-TASS still induced no toxic reaction. In rat plasma, IQCA-TASS formed nanoparticles with diameters of less than 41 nm. The interactions of the nanoparticles with both resting and activated platelets were imaged. IQCA-TASS should be a safe nano-medicine capable of targeting thrombus and releasing anti-thrombotic/anti-inflammatory pharmacophores in disease sites.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2016) studied Thrombosis. IQCA-TASS was evaluated. IQCA-TASS formed nanoparticles in rat plasma and induced no toxic reaction at 1000 times the minimal effective dose, indicating potential as a safe nano-medicine for targeting thrombus.
Synapse has enriched 10 related papers. Consider them for comparative context: